Genetic Variation Alters Response to Common Anti-clotting Drug
NIH, National Institute of General Medical Sciences (NIGMS)Millions of people take the anticoagulant drug warfarin to prevent harmful clotting after a heart attack, stroke, or major surgery. But the proper dose of warfarin can vary greatly and can be hard to predict. Some of this variability may boil down to a recently identified gene involved in blood clotting, according to a new study.